 - Patients must have relapsed or refractory Hodgkins Lymphoma HL defined as relapse following initial therapy or lack of response to first line therapy and treatment with second-line salvage therapy. Patients may have also undergone high-dose chemotherapy with autologous stem cell transplantation at least 12 weeks prior to study entry 